Harga Saham

Tanggal	Amicus Therapeutics Harga saham
23/8/2024	11,76 undefined
22/8/2024	11,70 undefined
21/8/2024	12,09 undefined
20/8/2024	11,92 undefined
19/8/2024	11,89 undefined
16/8/2024	11,47 undefined
15/8/2024	11,45 undefined
14/8/2024	11,50 undefined
13/8/2024	11,72 undefined
12/8/2024	11,58 undefined
9/8/2024	11,48 undefined
8/8/2024	11,32 undefined
7/8/2024	10,00 undefined
6/8/2024	9,94 undefined
5/8/2024	9,55 undefined
2/8/2024	10,08 undefined
1/8/2024	10,20 undefined
31/7/2024	10,31 undefined
30/7/2024	10,08 undefined
29/7/2024	10,11 undefined

Tanggal	Amicus Therapeutics Pendapatan	Amicus Therapeutics EBIT	Amicus Therapeutics Laba
2030e	1,28 miliar undefined	829,46 Juta. undefined	664,67 Juta. undefined
2029e	1,42 miliar undefined	749,43 Juta. undefined	954,71 Juta. undefined
2028e	1,30 miliar undefined	670,04 Juta. undefined	669,20 Juta. undefined
2027e	1,08 miliar undefined	482,73 Juta. undefined	472,82 Juta. undefined
2026e	827,88 Juta. undefined	269,60 Juta. undefined	190,77 Juta. undefined
2025e	652,93 Juta. undefined	108,58 Juta. undefined	65,33 Juta. undefined
2024e	527,36 Juta. undefined	-17,47 Juta. undefined	-56,73 Juta. undefined
2023	399,36 Juta. undefined	-76,08 Juta. undefined	-151,58 Juta. undefined
2022	329,20 Juta. undefined	-205,50 Juta. undefined	-236,60 Juta. undefined
2021	305,50 Juta. undefined	-206,40 Juta. undefined	-250,50 Juta. undefined
2020	260,90 Juta. undefined	-247,00 Juta. undefined	-276,90 Juta. undefined
2019	182,20 Juta. undefined	-304,10 Juta. undefined	-356,40 Juta. undefined
2018	91,20 Juta. undefined	-328,80 Juta. undefined	-349,00 Juta. undefined
2017	36,90 Juta. undefined	23,40 Juta. undefined	-284,00 Juta. undefined
2016	5,00 Juta. undefined	-181,80 Juta. undefined	-200,00 Juta. undefined
2015	0 undefined	-130,40 Juta. undefined	-132,10 Juta. undefined
2014	1,20 Juta. undefined	-68,80 Juta. undefined	-68,90 Juta. undefined
2013	400.000,00 undefined	-61,70 Juta. undefined	-59,60 Juta. undefined
2012	18,40 Juta. undefined	-52,90 Juta. undefined	-48,80 Juta. undefined
2011	21,40 Juta. undefined	-50,90 Juta. undefined	-44,40 Juta. undefined
2010	900.000,00 undefined	-55,80 Juta. undefined	-54,90 Juta. undefined
2009	64,40 Juta. undefined	-5,90 Juta. undefined	-6,60 Juta. undefined
2008	15,00 Juta. undefined	-44,00 Juta. undefined	-39,40 Juta. undefined
2007	1,80 Juta. undefined	-45,80 Juta. undefined	-41,50 Juta. undefined
2006	0 undefined	-46,90 Juta. undefined	-65,90 Juta. undefined
2005	0 undefined	-20,80 Juta. undefined	-20,10 Juta. undefined
2004	0 undefined	-8,50 Juta. undefined	-8,90 Juta. undefined

	Pendapatan	EBIT	Laba
2004	0 USD	-8,50 Juta. USD	-8,90 Juta. USD
2005	0 USD	-20,80 Juta. USD	-20,10 Juta. USD
2006	0 USD	-46,90 Juta. USD	-65,90 Juta. USD
2007	1,80 Juta. USD	-45,80 Juta. USD	-41,50 Juta. USD
2008	15,00 Juta. USD	-44,00 Juta. USD	-39,40 Juta. USD
2009	64,40 Juta. USD	-5,90 Juta. USD	-6,60 Juta. USD
2010	900.000,00 USD	-55,80 Juta. USD	-54,90 Juta. USD
2011	21,40 Juta. USD	-50,90 Juta. USD	-44,40 Juta. USD
2012	18,40 Juta. USD	-52,90 Juta. USD	-48,80 Juta. USD
2013	400.000,00 USD	-61,70 Juta. USD	-59,60 Juta. USD
2014	1,20 Juta. USD	-68,80 Juta. USD	-68,90 Juta. USD
2015	0 USD	-130,40 Juta. USD	-132,10 Juta. USD
2016	5,00 Juta. USD	-181,80 Juta. USD	-200,00 Juta. USD
2017	36,90 Juta. USD	23,40 Juta. USD	-284,00 Juta. USD
2018	91,20 Juta. USD	-328,80 Juta. USD	-349,00 Juta. USD
2019	182,20 Juta. USD	-304,10 Juta. USD	-356,40 Juta. USD
2020	260,90 Juta. USD	-247,00 Juta. USD	-276,90 Juta. USD
2021	305,50 Juta. USD	-206,40 Juta. USD	-250,50 Juta. USD
2022	329,20 Juta. USD	-205,50 Juta. USD	-236,60 Juta. USD
2023	399,36 Juta. USD	-76,08 Juta. USD	-151,58 Juta. USD
2024e	527,36 Juta. USD	-17,47 Juta. USD	-56,73 Juta. USD
2025e	652,93 Juta. USD	108,58 Juta. USD	65,33 Juta. USD
2026e	827,88 Juta. USD	269,60 Juta. USD	190,77 Juta. USD
2027e	1,08 miliar USD	482,73 Juta. USD	472,82 Juta. USD
2028e	1,30 miliar USD	670,04 Juta. USD	669,20 Juta. USD
2029e	1,42 miliar USD	749,43 Juta. USD	954,71 Juta. USD
2030e	1,28 miliar USD	829,46 Juta. USD	664,67 Juta. USD

2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023

4,30	24,40	54,70	161,50	121,10	78,20	107,40	55,70	99,10	82,00	151,70	214,00	330,40	358,60	504,20	452,70	483,30	482,50	293,60	286,20
0	0	0	0	0	0	0	5,00	3,20	1,10	0	0	1,30	9,50	22,00	33,30	46,90	52,70	66,20	87,63
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	3,40	4,60	8,40	14,00	19,60	26,80	23,80	59,70
0,20	0,40	0,30	1,50	2,50	2,30	2,20	5,90	2,30	5,20	2,90	2,60	5,00	19,30	16,60	20,00	29,70	34,80	40,20	49,53
4,50	24,80	55,00	163,00	123,60	80,50	109,60	66,60	104,60	88,30	154,60	216,60	340,10	392,00	551,20	520,00	579,50	596,80	423,80	483,06
0,50	3,30	4,40	3,80	4,90	4,40	2,60	2,40	5,00	4,10	2,80	6,20	9,80	9,10	11,40	81,00	67,20	63,10	60,30	57,98
0	0	0	0	0	0	0	0	0	0	17,50	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	23,00	23,00	486,70	486,70	23,00	23,00	23,00	23,00	23,00	23,00	20,49
0	0	0	0	0	0	0	0	0	11,60	11,60	197,80	197,80	197,80	197,80	197,80	197,80	197,80	197,80	197,80
0	0,50	0,30	0,30	0,30	0,50	0,30	0,70	0,40	0,60	0,50	1,10	2,50	5,20	6,70	28,30	19,10	24,40	19,20	18,55
0,50	3,80	4,70	4,10	5,20	4,90	2,90	3,10	5,40	39,30	55,40	691,80	696,80	235,10	238,90	330,10	307,10	308,30	300,30	294,82
0,01	0,03	0,06	0,17	0,13	0,09	0,11	0,07	0,11	0,13	0,21	0,91	1,04	0,63	0,79	0,85	0,89	0,91	0,72	0,78

20,00	60,50	124,20	0,30	0,30	0,30	0,40	0,40	0,60	0,70	1,00	1,30	1,50	1,70	1,90	2,60	2,70	2,80	2,80	2,92
0,00	0,00	0,01	0,23	0,23	0,24	0,29	0,30	0,39	0,42	0,57	0,92	1,12	1,40	1,74	2,23	2,31	2,60	2,66	2,84
-17,30	-37,30	-83,70	-124,80	-164,20	-170,80	-225,70	-270,10	-318,90	-378,50	-447,40	-570,80	-763,50	-1.047,50	-1.399,20	-1.756,20	-2.033,10	-2.295,80	-2.532,40	-2.684,00
-0,10	-2,50	0	0	0	0	0	0	0	0	0	0	1,90	-1,70	0,50	2,80	8,40	5,30	-12,00	5,43
0	0	0	400,00	500,00	0	0	0	0	0	-100,00	-100,00	100,00	-400,00	-400,00	0	-200,00	-300,00	-100,00	-188,00
4,20	24,70	46,60	103,30	71,00	71,80	64,90	29,60	69,20	45,80	122,20	347,90	360,20	352,90	342,90	476,40	286,40	307,40	123,00	160,17
0,60	0,90	1,20	0,50	2,00	3,80	2,00	2,60	2,10	2,10	5,90	16,50	12,90	16,40	44,40	51,40	17,10	21,50	15,40	15,12
0,20	1,40	7,70	9,90	6,80	5,80	6,30	7,10	6,70	8,00	10,50	15,70	27,80	37,20	36,20	68,90	88,40	95,20	88,70	129,76
0	0	0	3,80	3,70	0	6,60	8,50	0	0	0	41,40	70,00	16,20	5,50	8,60	24,20	29,30	34,90	22,81
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0,20	0,30	1,30	1,50	0,90	1,60	1,30	1,00	0,40	0,30	3,80	0	0,30	0,30	0	0	0	0	0	0
1,00	2,60	10,20	15,70	13,40	11,20	16,20	19,20	9,20	10,40	20,20	73,60	111,00	70,10	86,10	128,90	129,70	146,00	139,00	167,69
0	0,70	2,30	1,20	0,30	2,30	1,00	0	0,30	14,20	10,50	0	154,50	164,20	321,70	149,50	389,30	389,40	392,00	387,86
0	0	0	0	0	0	0	0	0	9,20	9,20	176,20	173,80	6,50	6,50	5,10	4,90	4,90	4,90	0
0	0,70	0,60	46,80	44,00	0	30,40	20,90	31,30	48,00	47,90	310,70	237,50	33,50	32,70	90,40	76,30	57,50	65,20	62,16
0	1,40	2,90	48,00	44,30	2,30	31,40	20,90	31,60	71,40	67,60	486,90	565,80	204,20	360,90	245,00	470,50	451,80	462,10	450,02
1,00	4,00	13,10	63,70	57,70	13,50	47,60	40,10	40,80	81,80	87,80	560,50	676,80	274,30	447,00	373,90	600,20	597,80	601,10	617,71
0,01	0,03	0,06	0,17	0,13	0,09	0,11	0,07	0,11	0,13	0,21	0,91	1,04	0,63	0,79	0,85	0,89	0,91	0,72	0,78

Amicus Therapeutics Margin Kotor	Amicus Therapeutics Margin Laba	Amicus Therapeutics Margin EBIT	Amicus Therapeutics Margin Laba
2030e	90,65 %	64,55 %	51,73 %
2029e	90,65 %	52,67 %	67,09 %
2028e	90,65 %	51,58 %	51,52 %
2027e	90,65 %	44,70 %	43,78 %
2026e	90,65 %	32,57 %	23,04 %
2025e	90,65 %	16,63 %	10,01 %
2024e	90,65 %	-3,31 %	-10,76 %
2023	90,65 %	-19,05 %	-37,96 %
2022	88,27 %	-62,42 %	-71,87 %
2021	88,71 %	-67,56 %	-82,00 %
2020	88,08 %	-94,67 %	-106,13 %
2019	87,98 %	-166,90 %	-195,61 %
2018	84,21 %	-360,53 %	-382,68 %
2017	83,20 %	63,41 %	-769,65 %
2016	82,00 %	-3.636,00 %	-4.000,00 %
2015	90,65 %	0 %	0 %
2014	90,65 %	-5.733,33 %	-5.741,67 %
2013	90,65 %	-15.425,00 %	-14.900,00 %
2012	90,65 %	-287,50 %	-265,22 %
2011	90,65 %	-237,85 %	-207,48 %
2010	90,65 %	-6.200,00 %	-6.100,00 %
2009	90,65 %	-9,16 %	-10,25 %
2008	90,65 %	-293,33 %	-262,67 %
2007	90,65 %	-2.544,44 %	-2.305,56 %
2006	90,65 %	0 %	0 %
2005	90,65 %	0 %	0 %
2004	90,65 %	0 %	0 %

	Margin Kotor	Margin EBIT	Margin Laba
2004	90,65 %	0 %	0 %
2005	90,65 %	0 %	0 %
2006	90,65 %	0 %	0 %
2007	90,65 %	-2.544,44 %	-2.305,56 %
2008	90,65 %	-293,33 %	-262,67 %
2009	90,65 %	-9,16 %	-10,25 %
2010	90,65 %	-6.200,00 %	-6.100,00 %
2011	90,65 %	-237,85 %	-207,48 %
2012	90,65 %	-287,50 %	-265,22 %
2013	90,65 %	-15.425,00 %	-14.900,00 %
2014	90,65 %	-5.733,33 %	-5.741,67 %
2015	90,65 %	0 %	0 %
2016	82,00 %	-3.636,00 %	-4.000,00 %
2017	83,20 %	63,41 %	-769,65 %
2018	84,21 %	-360,53 %	-382,68 %
2019	87,98 %	-166,90 %	-195,61 %
2020	88,08 %	-94,67 %	-106,13 %
2021	88,71 %	-67,56 %	-82,00 %
2022	88,27 %	-62,42 %	-71,87 %
2023	90,65 %	-19,05 %	-37,96 %
2024e	90,65 %	-3,31 %	-10,76 %
2025e	90,65 %	16,63 %	10,01 %
2026e	90,65 %	32,57 %	23,04 %
2027e	90,65 %	44,70 %	43,78 %
2028e	90,65 %	51,58 %	51,52 %
2029e	90,65 %	52,67 %	67,09 %
2030e	90,65 %	64,55 %	51,73 %

Tanggal	Amicus Therapeutics Pendapatan per Saham	Amicus Therapeutics EBIT per Saham	Amicus Therapeutics Laba per Saham
2030e	4,34 undefined	0 undefined	2,24 undefined
2029e	4,80 undefined	0 undefined	3,22 undefined
2028e	4,39 undefined	0 undefined	2,26 undefined
2027e	3,65 undefined	0 undefined	1,60 undefined
2026e	2,80 undefined	0 undefined	0,64 undefined
2025e	2,20 undefined	0 undefined	0,22 undefined
2024e	1,78 undefined	0 undefined	-0,19 undefined
2023	1,35 undefined	-0,26 undefined	-0,51 undefined
2022	1,14 undefined	-0,71 undefined	-0,82 undefined
2021	1,13 undefined	-0,76 undefined	-0,92 undefined
2020	1,01 undefined	-0,95 undefined	-1,07 undefined
2019	0,76 undefined	-1,26 undefined	-1,48 undefined
2018	0,49 undefined	-1,77 undefined	-1,88 undefined
2017	0,24 undefined	0,15 undefined	-1,85 undefined
2016	0,04 undefined	-1,35 undefined	-1,49 undefined
2015	0 undefined	-1,19 undefined	-1,20 undefined
2014	0,02 undefined	-0,92 undefined	-0,93 undefined
2013	0,01 undefined	-1,20 undefined	-1,16 undefined
2012	0,40 undefined	-1,16 undefined	-1,07 undefined
2011	0,62 undefined	-1,47 undefined	-1,28 undefined
2010	0,03 undefined	-2,01 undefined	-1,98 undefined
2009	2,85 undefined	-0,26 undefined	-0,29 undefined
2008	0,67 undefined	-1,96 undefined	-1,75 undefined
2007	0,14 undefined	-3,47 undefined	-3,14 undefined
2006	0 undefined	-2,11 undefined	-2,97 undefined
2005	0 undefined	-0,94 undefined	-0,91 undefined
2004	0 undefined	-0,38 undefined	-0,40 undefined

	Pendapatan per Saham	EBIT per Saham	Laba per Saham
2004	0 USD	-0,38 USD	-0,40 USD
2005	0 USD	-0,94 USD	-0,91 USD
2006	0 USD	-2,11 USD	-2,97 USD
2007	0,14 USD	-3,47 USD	-3,14 USD
2008	0,67 USD	-1,96 USD	-1,75 USD
2009	2,85 USD	-0,26 USD	-0,29 USD
2010	0,03 USD	-2,01 USD	-1,98 USD
2011	0,62 USD	-1,47 USD	-1,28 USD
2012	0,40 USD	-1,16 USD	-1,07 USD
2013	0,01 USD	-1,20 USD	-1,16 USD
2014	0,02 USD	-0,92 USD	-0,93 USD
2015	0 USD	-1,19 USD	-1,20 USD
2016	0,04 USD	-1,35 USD	-1,49 USD
2017	0,24 USD	0,15 USD	-1,85 USD
2018	0,49 USD	-1,77 USD	-1,88 USD
2019	0,76 USD	-1,26 USD	-1,48 USD
2020	1,01 USD	-0,95 USD	-1,07 USD
2021	1,13 USD	-0,76 USD	-0,92 USD
2022	1,14 USD	-0,71 USD	-0,82 USD
2023	1,35 USD	-0,26 USD	-0,51 USD
2024e	1,78 USD	0 USD	-0,19 USD
2025e	2,20 USD	0 USD	0,22 USD
2026e	2,80 USD	0 USD	0,64 USD
2027e	3,65 USD	0 USD	1,60 USD
2028e	4,39 USD	0 USD	2,26 USD
2029e	4,80 USD	0 USD	3,22 USD
2030e	4,34 USD	0 USD	2,24 USD

	Jumlah Saham
2004	22,20 Juta. Aktien
2005	22,20 Juta. Aktien
2006	22,20 Juta. Aktien
2007	13,20 Juta. Aktien
2008	22,50 Juta. Aktien
2009	22,60 Juta. Aktien
2010	27,70 Juta. Aktien
2011	34,60 Juta. Aktien
2012	45,60 Juta. Aktien
2013	51,30 Juta. Aktien
2014	74,40 Juta. Aktien
2015	109,90 Juta. Aktien
2016	134,40 Juta. Aktien
2017	153,40 Juta. Aktien
2018	185,80 Juta. Aktien
2019	240,40 Juta. Aktien
2020	258,90 Juta. Aktien
2021	271,40 Juta. Aktien
2022	289,10 Juta. Aktien
2023	295,16 Juta. Aktien
2024e	295,16 Juta. Aktien
2025e	295,16 Juta. Aktien
2026e	295,16 Juta. Aktien
2027e	295,16 Juta. Aktien
2028e	295,16 Juta. Aktien
2029e	295,16 Juta. Aktien
2030e	295,16 Juta. Aktien

Tanggal	Estimasi EPS	EPS-Actual	Kuartal Laporan
30/6/2024	-0,06	-0,05 (11,66 %)	2024 Q2
31/3/2024	-0,07	-0,16 (-139,16 %)	2024 Q1
31/12/2023	-0,06	-0,11 (-83,03 %)	2023 Q4
30/9/2023	-0,08	-0,07 (9,21 %)	2023 Q3
30/6/2023	-0,13	-0,15 (-19,24 %)	2023 Q2
31/3/2023	-0,15	-0,18 (-20,32 %)	2023 Q1
31/12/2022	-0,13	-0,19 (-47,40 %)	2022 Q4
30/9/2022	-0,19	-0,12 (36,88 %)	2022 Q3
30/6/2022	-0,22	-0,21 (5,11 %)	2022 Q2
31/3/2022	-0,26	-0,30 (-15,34 %)	2022 Q1
31/12/2021	-0,16	-0,29 (-82,28 %)	2021 Q4
30/9/2021	-0,17	-0,19 (-10,79 %)	2021 Q3
30/6/2021	-0,22	-0,19 (11,87 %)	2021 Q2
31/3/2021	-0,24	-0,25 (-4,30 %)	2021 Q1
31/12/2020	-0,22	-0,27 (-21,90 %)	2020 Q4
30/9/2020	-0,22	-0,23 (-2,91 %)	2020 Q3
30/6/2020	-0,27	-0,20 (24,67 %)	2020 Q2
31/3/2020	-0,29	-0,34 (-17,65 %)	2020 Q1
31/12/2019	-0,28	-0,35 (-25,67 %)	2019 Q4
30/9/2019	-0,33	-0,24 (26,45 %)	2019 Q3
30/6/2019	-0,33	-0,36 (-8,40 %)	2019 Q2
31/3/2019	-0,31	-0,39 (-23,85 %)	2019 Q1
31/12/2018	-0,28	-0,41 (-44,01 %)	2018 Q4
30/9/2018	-0,28	-0,31 (-9,93 %)	2018 Q3
30/6/2018	-0,33	-0,33 (0,96 %)	2018 Q2
31/3/2018	-0,37	-0,28 (24,45 %)	2018 Q1
31/12/2017	-0,30	-0,41 (-35,49 %)	2017 Q4
30/9/2017	-0,32	-0,41 (-29,66 %)	2017 Q3
30/6/2017	-0,37	-0,34 (6,98 %)	2017 Q2
31/3/2017	-0,37	-0,39 (-6,79 %)	2017 Q1
31/12/2016	-0,34	-0,42 (-24,30 %)	2016 Q4
30/9/2016	-0,32	-0,33 (-2,71 %)	2016 Q3
30/6/2016	-0,34	-0,40 (-18,84 %)	2016 Q2
31/3/2016	-0,35	-0,35 (-1,42 %)	2016 Q1
31/12/2015	-0,31	-0,36 (-15,72 %)	2015 Q4
30/9/2015	-0,25	-0,32 (-27,54 %)	2015 Q3
30/6/2015	-0,25	-0,26 (-5,09 %)	2015 Q2
31/3/2015	-0,21	-0,25 (-19,56 %)	2015 Q1
31/12/2014	-0,18	-0,24 (-30,72 %)	2014 Q4
30/9/2014	-0,21	-0,22 (-2,71 %)	2014 Q3
30/6/2014	-0,24	-0,22 (7,25 %)	2014 Q2
31/3/2014	-0,25	-0,25 (-1,05 %)	2014 Q1
31/12/2013	-0,33	-0,18 (45,19 %)	2013 Q4
30/9/2013	-0,35	-0,29 (16,79 %)	2013 Q3
30/6/2013	-0,35	-0,31 (12,08 %)	2013 Q2
31/3/2013	-0,33	-0,35 (-5,36 %)	2013 Q1
31/12/2012	-0,38	-0,20 (47,62 %)	2012 Q4
30/9/2012	-0,24	-0,34 (-38,89 %)	2012 Q3
30/6/2012	-0,24	-0,20 (15,29 %)	2012 Q2
31/3/2012	-0,36	-0,35 (3,34 %)	2012 Q1
31/12/2011	-0,38	-0,25 (34,35 %)	2011 Q4
30/9/2011	-0,34	-0,28 (17,65 %)	2011 Q3
30/6/2011	-0,32	-0,37 (-14,80 %)	2011 Q2
31/3/2011	-0,36	-0,39 (-9,24 %)	2011 Q1
31/12/2010	-0,16	-0,48 (-209,68 %)	2010 Q4
30/9/2010	-0,50	-0,56 (-11,47 %)	2010 Q3
30/6/2010	-0,54	-0,41 (24,16 %)	2010 Q2
31/3/2010	-0,59	-0,54 (8,72 %)	2010 Q1
31/12/2009	-0,60	1,52 (352,58 %)	2009 Q4
30/9/2009	-0,70	-0,59 (15,56 %)	2009 Q3
30/6/2009	-0,67	-0,60 (10,19 %)	2009 Q2
31/3/2009	-0,65	-0,55 (15,75 %)	2009 Q1
31/12/2008	-0,63	-0,63 (0,38 %)	2008 Q4
30/9/2008	-0,48	-0,36 (24,91 %)	2008 Q3
30/6/2008	-0,53	-0,41 (21,95 %)	2008 Q2
31/3/2008	-0,39	-0,34 (11,71 %)	2008 Q1
31/12/2007	-0,41	-0,53 (-29,90 %)	2007 Q4
30/9/2007	-0,47	-0,46 (1,96 %)	2007 Q3
30/6/2007	-0,49	-1,37 (-178,34 %)	2007 Q2

%	Nama	Saham	Perubahan	Tanggal
9,61 %	The Vanguard Group, Inc.	28.450.070	1.360.613	31/12/2023
9,47 %	Perceptive Advisors LLC	28.057.456	364.539	31/12/2023
9,25 %	Avoro Capital Advisors LLC	27.400.000	0	31/12/2023
6,97 %	BlackRock Institutional Trust Company, N.A.	20.651.163	1.971.281	31/12/2023
5,13 %	Wellington Management Company, LLP	15.190.024	7.666.335	31/12/2023
5,01 %	Redmile Group, LLC	14.828.321	-2.116.300	31/12/2023
4,44 %	State Street Global Advisors (US)	13.163.085	1.790.649	31/12/2023
3,94 %	JP Morgan Asset Management	11.670.883	4.804.623	31/12/2023
3,93 %	William Blair Investment Management, LLC	11.647.026	1.270.263	31/12/2023
3,88 %	Janus Henderson Investors	11.507.129	-3.426.892	31/12/2023
3,84 %	Morgan Stanley & Co. LLC	11.380.117	1.254.072	31/12/2023
3,50 %	Palo Alto Investors LP	10.373.715	-150.307	31/12/2023
2,44 %	Macquarie Investment Management	7.215.010	2.358	31/12/2023
2,36 %	Pictet Asset Management Ltd.	6.994.597	-1.402.914	31/12/2023
2,01 %	Geode Capital Management, L.L.C.	5.951.295	345.129	31/12/2023
1,80 %	JPMorgan Asset Management U.K. Limited	5.323.591	-143.025	31/12/2023
1,71 %	Fiera Capital Corporation	5.061.644	-24.227	31/12/2023
1,55 %	American Century Investment Management, Inc.	4.582.067	238.197	31/12/2023
1,33 %	DWS Investments UK Limited	3.951.977	3.818.630	31/12/2023
0,85 %	Norges Bank Investment Management (NBIM)	2.531.000	-2.869.086	31/12/2023
0,84 %	Novo Holdings A/S	2.500.000	404.100	31/12/2023
0,84 %	Northern Trust Investments, Inc.	2.492.674	97.960	31/12/2023
0,82 %	MFS Investment Management	2.415.090	593.131	31/12/2023
0,77 %	Charles Schwab Investment Management, Inc.	2.268.886	90.195	31/12/2023
0,74 %	Fidelity Management & Research Company LLC	2.194.460	-583.703	31/12/2023
0,68 %	Invus Public Equities Advisors, LLC	2.026.364	-2.036.203	31/12/2023
0,61 %	DWS Investment S.A.	1.812.149	1.812.149	31/12/2023
0,59 %	Victory Capital Management Inc.	1.752.687	-1.196.519	31/12/2023
0,59 %	Goldman Sachs & Company, Inc.	1.741.597	-88.568	31/12/2023
0,57 %	Pictet Asset Management (Japan) Ltd.	1.692.993	439.503	31/10/2023
0,53 %	Balyasny Asset Management LP	1.556.540	-1.828.892	31/12/2023
0,50 %	Finepoint Capital LP	1.489.025	0	31/12/2023
0,50 %	New York State Common Retirement Fund	1.475.212	1.039	31/12/2023
0,47 %	PanAgora Asset Management Inc.	1.397.312	-33.112	31/12/2023
0,47 %	Nuveen LLC	1.392.742	152.535	31/12/2023
0,43 %	Great Point Partners, LLC	1.280.500	423.500	31/12/2023
0,42 %	Clarus Ventures, LLC	1.233.552	1.233.552	31/12/2023
0,42 %	Blackstone Alternative Credit Advisors LP	1.233.552	1.233.552	31/12/2023
0,41 %	T. Rowe Price Associates, Inc.	1.228.659	-23.851	31/12/2023
0,39 %	Managed Account Advisors LLC	1.143.052	-472.002	31/12/2023
0,37 %	PRIMECAP Management Company	1.094.200	0	31/12/2023
0,37 %	BlackRock Financial Management, Inc.	1.093.483	68.591	31/12/2023
0,36 %	Rice Hall James & Associates, LLC	1.065.965	-12.900	31/12/2023
0,36 %	Rock Springs Capital Management LP	1.063.806	0	31/12/2023
0,36 %	BofA Global Research (US)	1.062.845	433.266	31/12/2023
0,36 %	Morgan Stanley Investment Management Inc. (US)	1.055.476	1.050.060	31/12/2023
0,33 %	Voya Investment Management LLC	970.313	239.792	31/12/2023
0,32 %	Cutter Capital Management, LP	947.418	947.418	31/12/2023
0,31 %	BNP Paribas Securities Corp. North America	923.045	536.480	31/12/2023
0,29 %	StemPoint Capital LP	862.815	862.815	31/12/2023
0,29 %	abrdn Inc.	861.508	861.508	29/2/2024
0,28 %	UBS Financial Services, Inc.	824.708	303.038	31/12/2023
0,27 %	OrbiMed Advisors, LLC	806.000	806.000	31/12/2023
0,27 %	Rafferty Asset Management LLC	795.351	87.112	31/12/2023
0,26 %	Candriam Luxembourg S.A.	759.823	0	29/2/2024
0,25 %	BNY Mellon Asset Management	749.242	1.737	31/12/2023
0,25 %	Voloridge Investment Management, LLC	734.867	734.867	31/12/2023
0,24 %	Barclays Bank PLC	724.227	315.439	31/12/2023
0,24 %	Neuberger Berman, LLC	717.714	171.029	31/12/2023
0,24 %	BioImpact Capital LLC	715.883	-256	31/12/2023
0,24 %	BlackRock Investment Management, LLC	715.574	13.306	31/12/2023
0,24 %	M&G Investment Management Ltd.	710.557	509.632	31/12/2023
0,22 %	Medical Strategy GmbH	654.742	0	31/12/2023
0,20 %	Peregrine Capital Management, LLC	605.348	-123.337	31/12/2023
0,19 %	Candriam Belgium S.A.	553.879	-25.000	31/12/2023
0,17 %	JPMorgan Private Bank (United States)	515.649	206.395	31/12/2023
0,17 %	Schroder Investment Management Ltd. (SIM)	510.000	510.000	31/12/2023
0,17 %	Wells Fargo Advisors	495.047	-14.688	31/12/2023
0,17 %	Columbia Threadneedle Investments (US)	489.756	109.622	31/12/2023
0,16 %	Campbell (Bradley Lewis)	473.777	0	1/4/2024
0,16 %	Citi Investment Research (US)	471.318	96.651	31/12/2023
0,15 %	CM Management, LLC	450.000	0	31/12/2023
0,14 %	Schweizerische Nationalbank	424.400	-44.800	31/12/2023
0,14 %	Envestnet Asset Management, Inc.	415.382	21.654	31/12/2023
0,14 %	Rhumbline Advisers Ltd. Partnership	402.640	-13.480	31/12/2023
0,13 %	Mellon Investments Corporation	387.065	3.294	31/12/2023
0,13 %	Conestoga Capital Advisors, LLC	375.202	-10.180	29/2/2024
0,13 %	ExodusPoint Capital Management, LP	372.380	-569.053	31/12/2023
0,12 %	Goldman Sachs Asset Management, L.P.	367.757	-295.357	31/12/2023
0,12 %	Hudson Bay Capital Management LP	360.000	185.000	31/12/2023
0,12 %	Silvercrest Asset Management Group LLC	358.925	-74	31/12/2023
0,11 %	AllianceBernstein L.P.	340.349	3.000	31/12/2023
0,11 %	Parametric Portfolio Associates LLC	339.971	14.794	31/12/2023
0,11 %	BlackRock Advisors (UK) Limited	336.870	12.488	31/3/2024
0,11 %	Credit Suisse Funds AG	326.217	4.816	31/12/2023
0,11 %	J.P. Morgan Securities LLC	320.034	-20.380	31/12/2023
0,11 %	HOOPP Investment Management	318.500	43.000	31/12/2023
0,10 %	Transcend Capital Advisors, LLC	309.978	23.474	31/12/2023
0,10 %	Caption Management, LLC	299.500	272.500	31/12/2023
0,10 %	Hillsdale Investment Management Inc.	294.300	23.640	31/12/2023
0,10 %	D. E. Shaw & Co., L.P.	286.224	-73.967	31/12/2023
0,09 %	Northern Trust Global Investments	273.054	-47.039	31/12/2023
0,09 %	Ambassador Advisors, LLC	270.993	-1.180	31/12/2023
0,09 %	BlackRock Asset Management Ireland Limited	266.911	20.636	31/12/2023
0,09 %	Jane Street Capital, L.L.C.	262.333	129.730	31/12/2023
0,09 %	Allianz Global Investors GmbH	262.332	7.478	31/12/2023
0,09 %	FundLogic SAS	260.870	194.317	31/12/2023
0,09 %	New Jersey Division of Investment	253.532	46.541	31/12/2023
0,09 %	Simplex Trading, LLC	251.989	220.670	31/12/2023
0,08 %	Quimi (Daphne)	249.991	-14.605	12/4/2023

What values and corporate philosophy does Amicus Therapeutics represent?

Amicus Therapeutics Inc represents values of innovation, dedication, and patient-centricity. With a corporate philosophy focused on delivering life-changing therapies, Amicus strives to improve the lives of individuals with rare and devastating diseases. The company is committed to advancing science, developing transformative medicines, and ensuring access to those therapies for patients in need. Amicus fosters a collaborative and compassionate approach, working closely with patient advocacy groups, healthcare professionals, and regulatory authorities to make a meaningful impact in the lives of the communities it serves.

In which countries and regions is Amicus Therapeutics primarily present?

Amicus Therapeutics Inc is primarily present in the United States.

What significant milestones has the company Amicus Therapeutics achieved?

Amicus Therapeutics Inc has achieved significant milestones in its journey. Some notable accomplishments include the approval of Galafold, a breakthrough therapy for Fabry disease, by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Additionally, the company has made remarkable progress in developing innovative therapies for rare genetic diseases such as Pompe disease and other lysosomal storage disorders. Amicus Therapeutics Inc has successfully conducted clinical trials and obtained positive results, showcasing their commitment to advancing medical science and improving patients' lives. Their unwavering dedication has positioned them as a leading player in the biopharmaceutical industry.

What is the history and background of the company Amicus Therapeutics?

Amicus Therapeutics Inc is a biopharmaceutical company headquartered in Cranbury, New Jersey. Founded in 2002, Amicus Therapeutics focuses on developing advanced therapies for rare and orphan diseases. The company's innovative approach is based on the principles of personalized medicine, utilizing breakthrough science and technology. Over the years, Amicus Therapeutics has established itself as a leader in the field, with a strong dedication to improving the lives of patients with devastating genetic diseases. Through its robust research and development efforts, Amicus Therapeutics has successfully advanced several potential treatments, striving to bring hope and transformative therapies to those in need.

Who are the main competitors of Amicus Therapeutics in the market?

The main competitors of Amicus Therapeutics Inc in the market include companies such as Vertex Pharmaceuticals, BioMarin Pharmaceutical, and Sanofi Genzyme.

In which industries is Amicus Therapeutics primarily active?

Amicus Therapeutics Inc is primarily active in the biotechnology industry.

What is the business model of Amicus Therapeutics?

The business model of Amicus Therapeutics Inc. revolves around developing advanced therapies for rare and orphan diseases. The company focuses on utilizing its Chaperone-Advanced Replacement Therapy (CHART™) platform to deliver enzyme replacement therapies (ERTs) for individuals suffering from lysosomal storage disorders (LSDs). As a biopharmaceutical company, Amicus Therapeutics aims to address unmet medical needs through innovative drug research and development. By leveraging their expertise in protein misfolding and folding, Amicus Therapeutics aims to improve the lives of patients with genetic diseases.

Berapa KGV dari Amicus Therapeutics 2024?

Rasio P/E Amicus Therapeutics adalah -61,18.

KUV apa yang dimiliki oleh Amicus Therapeutics 2024?

Rasio KUV dari Amicus Therapeutics adalah 6,58.

Skor Kualitas AlleAktien apa yang dimiliki oleh Amicus Therapeutics?

Skor Kualitas AlleAktien untuk Amicus Therapeutics adalah 4/10.

Berapa jumlah pendapatan dari Amicus Therapeutics 2024?

Omset diharapkan Amicus Therapeutics adalah 527,36 Juta. USD.

Berapa besar keuntungan dari Amicus Therapeutics 2024?

Laba diharapkan Amicus Therapeutics adalah -56,73 Juta. USD.

Apa yang dilakukan Amicus Therapeutics?

Amicus Therapeutics Inc (Nasdaq: FOLD) aims to develop and manufacture novel therapies for people with rare and severe diseases. The biotechnology company, based in Cranbury, New Jersey, USA, focuses on researching and developing drugs that aim to influence the natural metabolism of proteins in the body to treat diseases caused by mutations in genes. The business model of Amicus Therapeutics is based on the discovery and development of therapies specialized in treating rare and severe diseases. The company works closely with patients and their families to gain a better understanding of the needs and challenges of these patient groups. Amicus utilizes a proprietary technology platform called Chaperon-Advanced Replacement Therapy (CHART), which allows for the treatment of Ectopic Glycosylation Disorders (EGS) by replacing faulty proteins produced by gene mutations with functional and stable therapeutics. Amicus Therapeutics specializes in the following three areas: 1. Fabry disease: A rare lysosomal metabolic disorder where the Alpha-Galactosidase-A enzyme is not produced normally due to mutations in the GLA gene. Amicus has developed Galafold, the first oral medication for treating Fabry disease, which aims to stabilize the faulty protein. 2. Pompe disease: A lysosomal storage disease characterized by a deficiency of enzymes that help in breaking down glycogen. This results in an accumulation of glycogen in various tissues and organs. Amicus has developed ATB200/AT2221, a combined therapy of enzyme replacement therapy and chaperone therapy aimed at correcting the enzyme deficiency caused by mutation. 3. Phenylketonuria (PKU): A metabolic disorder where an individual lacks the ability to metabolize phenylalanine. This leads to an accumulation of phenylalanine in the body, which can cause impairments to the central nervous system. Amicus has a pipeline of therapeutics in development for treating PKU, including a chaperone platform and an enzyme replacement therapy. Amicus Therapeutics collaborates closely with medical centers, patient organizations, and research institutions to develop innovative therapies for rare and severe diseases. The company is committed to enhancing the effectiveness and safety of medications, helping to improve the quality of life for affected individuals. By focusing on rare and severe diseases, Amicus Therapeutics can serve a niche and position itself as an innovator in the biotechnology industry. Overall, Amicus Therapeutics' business model has the potential to achieve significant medical advancements while also being profitable. The company is well-positioned to continue developing innovative therapies for rare and severe diseases that can improve the lives of patients and their families.

Berapa besar dividen Amicus Therapeutics?

Amicus Therapeutics membayarkan dividen sebesar 0 USD yang dibagi melalui pembayaran dalam setahun.

Berapa kali Amicus Therapeutics membayar dividen?

Dividen untuk Amicus Therapeutics saat ini tidak dapat dihitung atau perusahaan tidak membagikan dividen.

Apa itu ISIN Amicus Therapeutics?

ISIN dari Amicus Therapeutics adalah US03152W1099.

Apa itu Amicus Therapeutics WKN?

WKN dari Amicus Therapeutics adalah A0MSMZ.

Apa itu Ticker Amicus Therapeutics?

Ticker dari Amicus Therapeutics adalah FOLD.

Berapa banyak Dividen yang dibayarkan oleh Amicus Therapeutics?

Dalam 12 bulan terakhir, Amicus Therapeutics membayar dividen sebesar . Ini setara dengan yield dividen sekitar . Untuk 12 bulan mendatang, Amicus Therapeutics diperkirakan akan membayar dividen sebesar 0 USD.

Berapa tingkat dividen dari Amicus Therapeutics?

Imbal hasil dividen dari Amicus Therapeutics saat ini adalah .

Kapan Amicus Therapeutics membayar dividen?

Amicus Therapeutics membayar dividen setiap kuartal. Dividen ini dibayarkan pada bulan .

Seberapa aman dividen dari Amicus Therapeutics?

Amicus Therapeutics membayar dividen setiap tahun dalam 0 tahun terakhir.

Berapa besar dividen dari Amicus Therapeutics?

Untuk 12 bulan ke depan, diperkirakan akan ada dividen sebesar 0 USD. Ini setara dengan yield dividen sebesar 0 %.

Di sektor manakah Amicus Therapeutics berada?

Amicus Therapeutics dikelompokkan dalam sektor 'Kesehatan'.

Wann musste ich die Aktien von Amicus Therapeutics kaufen, um die vorherige Dividende zu erhalten?

Untuk menerima dividen terakhir dari Amicus Therapeutics tanggal 25/8/2024 sejumlah 0 USD, Anda harus memiliki saham tersebut di portofolio sebelum tanggal Ex-Tag pada 25/8/2024.

Kapan Amicus Therapeutics membayar dividen terakhir?

Pembayaran dividen terakhir dilakukan pada 25/8/2024.

Berapa besarnya dividen dari Amicus Therapeutics pada tahun 2023?

Pada tahun 2023, Amicus Therapeutics 0 USD telah dibayarkan sebagai dividen.

Dalam mata uang apa Amicus Therapeutics membayar dividen?

Dividen dari Amicus Therapeutics dibayarkan dalam USD.

2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e	2027e	2028e	2029e	2030e
0	0	0	0	0,00	0,02	0,06	0	0,02	0,02	0	0,00	0	0,01	0,04	0,09	0,18	0,26	0,31	0,33	0,40	0,53	0,65	0,83	1,08	1,30	1,42	1,28
-	-	-	-	-	1.400,00	326,67	-	-	-14,29	-	-	-	-	620,00	152,78	100,00	42,86	17,31	7,87	21,28	32,08	23,72	26,84	30,59	20,28	9,55	-9,77
-	-	-	-	-	-	-	-	-	-	-	-	-	80,00	83,33	83,52	87,91	88,08	88,85	88,15	90,73	-	-	-	-	-	-	-
0	0	0	0	0	0	0	0	0	0	0	0	0	4,00	30,00	76,00	160,00	229,00	271,00	290,00	362,00	0	0	0	0	0	0	0
-5,00	-8,00	-20,00	-46,00	-45,00	-44,00	-5,00	-55,00	-50,00	-52,00	-61,00	-68,00	-130,00	-181,00	23,00	-328,00	-304,00	-247,00	-206,00	-205,00	-76,00	-17,00	108,00	269,00	482,00	670,00	749,00	829,00
-	-	-	-	-4.500,00	-293,33	-7,81	-	-238,10	-288,89	-	-6.800,00	-	-3.620,00	63,89	-360,44	-167,03	-95,00	-67,54	-62,31	-19,05	-3,23	16,56	32,53	44,63	51,58	52,64	64,56
-6,00	-8,00	-20,00	-65,00	-41,00	-39,00	-6,00	-54,00	-44,00	-48,00	-59,00	-68,00	-132,00	-200,00	-284,00	-349,00	-356,00	-276,00	-250,00	-236,00	-151,00	-56,00	65,00	190,00	472,00	669,00	954,00	664,00
-	33,33	150,00	225,00	-36,92	-4,88	-84,62	800,00	-18,52	9,09	22,92	15,25	94,12	51,52	42,00	22,89	2,01	-22,47	-9,42	-5,60	-36,02	-62,91	-216,07	192,31	148,42	41,74	42,60	-30,40
22,20	22,20	22,20	22,20	13,20	22,50	22,60	27,70	34,60	45,60	51,30	74,40	109,90	134,40	153,40	185,80	240,40	258,90	271,40	289,10	295,16	0	0	0	0	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
-6,00	-8,00	-19,00	-46,00	-41,00	-39,00	-6,00	-54,00	-44,00	-48,00	-59,00	-68,00	-132,00	-200,00	-284,00	-349,00	-356,00	-276,00	-250,00	-236,00	-151,00
0	0	0	0	1,00	1,00	2,00	2,00	1,00	1,00	1,00	1,00	1,00	3,00	3,00	4,00	4,00	8,00	6,00	5,00	7,00
0	0	0	0	0	0	0	0	0	0	0	0	0	-3,00	-167,00	0	-1,00	0	0	0	-4,00
1,00	-1,00	0	6,00	50,00	-5,00	-46,00	31,00	-12,00	7,00	4,00	9,00	14,00	1,00	-24,00	-4,00	11,00	-32,00	-28,00	-39,00	-47,00
1,00	0	0	4,00	4,00	12,00	15,00	13,00	14,00	11,00	13,00	12,00	25,00	66,00	281,00	78,00	135,00	116,00	128,00	181,00	213,00
0	0	0	0	0	0	0	0	0	0	0	1,00	0	2,00	7,00	7,00	16,00	24,00	30,00	34,00	36,00
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	10,00	20,00	1,00	8,00
-3,00	-9,00	-18,00	-33,00	15,00	-36,00	-43,00	-13,00	-49,00	-33,00	-45,00	-51,00	-100,00	-150,00	-213,00	-299,00	-250,00	-233,00	-202,00	-166,00	-69,00
-1,00	0	-3,00	-2,00	0	-2,00	-1,00	0	-1,00	-4,00	0	0	-4,00	-5,00	-4,00	-6,00	-20,00	-3,00	-3,00	-3,00	-7,00
-1,00	-4,00	-16,00	-26,00	-75,00	21,00	31,00	-19,00	46,00	-39,00	26,00	-107,00	-145,00	-4,00	-171,00	-121,00	95,00	-13,00	78,00	92,00	98,00
0	-4,00	-13,00	-24,00	-74,00	24,00	33,00	-19,00	47,00	-35,00	26,00	-106,00	-140,00	1,00	-166,00	-114,00	115,00	-10,00	82,00	96,00	105,00
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
3,00	1,00	0	0	-1,00	-1,00	2,00	-1,00	-1,00	0	14,00	0	34,00	192,00	0	146,00	0	230,00	0	0	-20,00
0	12,00	40,00	63,00	92,00	0	0	45,00	0	81,00	15,00	139,00	258,00	100,00	259,00	307,00	201,00	42,00	229,00	4,00	103,00
3,00	13,00	41,00	66,00	91,00	-1,00	2,00	43,00	0	81,00	29,00	139,00	290,00	272,00	247,00	450,00	217,00	262,00	212,00	-7,00	61,00
0	0	1,00	3,00	0	0	0	0	0	0	0	0	-2,00	-19,00	-11,00	-2,00	16,00	-10,00	-16,00	-11,00	-20,00
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
-1,00	0	6,00	5,00	32,00	-16,00	-8,00	10,00	-3,00	8,00	9,00	-19,00	45,00	117,00	-136,00	31,00	63,00	19,00	83,00	-96,00	96,00
-4,97	-9,46	-21,16	-35,92	14,52	-39,53	-45,18	-14,36	-50,84	-38,06	-46,49	-51,91	-104,96	-156,10	-218,23	-306,27	-270,43	-236,52	-206,37	-170,35	-76,53
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Emisi Langsung.	—
Emisi tidak langsung dari energi yang dibeli.	—
Emisi tidak langsung dalam rantai nilai	—
Emisi CO₂	—
Strategi Reduksi CO₂	✅
Energi Batubara	❌
Energi Nuklir	❌
Percobaan pada hewan	✅
Bulu & Kulit	—
Pestisida	—
Minyak Sawit	—
Tembakau	❌
Bioteknologi	❌
Konsep Iklim	—
Pengelolaan Hutan Berkelanjutan	—
Peraturan Daur Ulang	❌
Kemasan Ramah Lingkungan	❌
Bahan berbahaya	❌
Konsumsi dan Efisiensi Bahan Bakar	❌
Penggunaan dan Efisiensi Air	✅

Persentase Karyawan Wanita	57
Proporsi Wanita dalam Manajemen	—
Porsi Karyawan Asia	—
Porsi Manajemen Asia	—
Proporsi Karyawan Hispanik/Latino	—
Porsi Manajemen Hispanik/Latino	—
Porsi Karyawan Berkulit Hitam	—
Porsi Manajemen Hitam	—
Proporsi Karyawan Kulit Putih	—
Porsi manajemen berkulit putih	—
Konten Dewasa	❌
Alkohol	❌
Pertahanan	—
Senjata api	❌
Judi	❌
Kontrak Militer	❌
Konsep Hak Asasi Manusia	✅
Konsep Perlindungan Data	—
Kesehatan dan Keselamatan Kerja	✅
Katolik	✅

Laporan Keberlanjutan	✅
Stakeholder-Engagement	❌
Kebijakan Pemanggilan Kembali	❌
Hukum Anti Monopoli	❌

Bursa	Amicus Therapeutics Ticker
DÜSSELDORF	AM6.DU
FRANKFURT	AM6.F
LONDON	0HF9.L
LONDON STOCK EXCHANGE	0HF9.L
MÜNCHEN	AM6.MU
NASDAQ	FOLD

Amicus Therapeutics Ticker	Amicus Therapeutics FIGI
AM6:GR	BBG000F0TV39
AM6:GF	BBG000F0TVG5
AM6:GD	BBG000F0TVT1
AM6:GS	BBG000F0VYF7
AM6:GM	BBG000F0VZ55
AM6:GB	BBG000F0VZK8
FOLD:US	BBG000PLF6N0
FOLD:UA	BBG000PLF7J3
FOLD:UC	BBG000PLF7M9
FOLD:UN	BBG000PLF810
FOLD:UP	BBG000PLF8J1
FOLD:UQ	BBG000PLF8M7
FOLD:UB	BBG000PLF9T8
FOLD:UM	BBG000PLFBV0
FOLD:UX	BBG000PLFC48
FOLD:UD	BBG000PLFGG6
FOLD:UF	BBG000PLFHJ1
FOLD:VY	BBG000PLFHQ3
FOLD:VJ	BBG000PLFHT0
FOLD:VK	BBG000PLFJ43
FOLD:VF	BBG00DJGGGP5
AM6:TH	BBG00H45FFR7
FOLDEUR:EO	BBG00H4G0DD9
FOLDEUR:XH	BBG00H4G0DH5
FOLDEUR:XF	BBG00H4G0DK1
FOLDEUR:XE	BBG00H4G0DM9
FOLDEUR:XJ	BBG00H4G0DN8
FOLDEUR:XL	BBG00H4G0DP6
FOLDEUR:XG	BBG00H4G0DQ5
FOLDEUR:XO	BBG00H4G0DR4
FOLDEUR:XS	BBG00H4G0DW8
FOLDEUR:XA	BBG00H4G0DX7
FOLDEUR:E1	BBG00H4G0DY6
FOLDEUR:XT	BBG00H4G0DZ5
FOLDEUR:XW	BBG00H4G0F08
FOLDEUR:XU	BBG00H4G0F17
FOLDEUR:XV	BBG00H4G0F26
FOLDEUR:EU	BBG00H4G0F44
AM6:QT	BBG00H50QP84
FOLDEUR:XX	BBG00JN8MYF0
FOLDUSD:X2	BBG00JQBM439
FOLDUSD:XB	BBG00JQBM448
FOLDUSD:XH	BBG00JQBM466
FOLDUSD:XF	BBG00JQBM484
FOLDUSD:XE	BBG00JQBM4B0
FOLDUSD:XJ	BBG00JQBM4C9
FOLDUSD:XL	BBG00JQBM4D8
FOLDUSD:XG	BBG00JQBM4F6
FOLDUSD:XO	BBG00JQBM4G5
FOLDUSD:XS	BBG00JQBM4L9
FOLDUSD:XA	BBG00JQBM4M8
FOLDUSD:E1	BBG00JQBM4N7
FOLDUSD:XT	BBG00JQBM4P5
FOLDUSD:XW	BBG00JQBM4Q4
FOLDUSD:XU	BBG00JQBM4R3
FOLDUSD:XV	BBG00JQBM4S2
FOLDUSD:XM	BBG00JQBM4T1
FOLDUSD:XQ	BBG00JQBM4W7
FOLDUSD:XX	BBG00JQBM4X6
FOLDUSD:XZ	BBG00JQBM4Y5
FOLDUSD:EU	BBG00JQBM509
0HF9:LN	BBG00JVRN5G0
FOLDGBX:X2	BBG00K2PDF36
FOLDGBX:XB	BBG00K2PDF45
FOLDGBX:XH	BBG00K2PDF63
FOLDGBX:XF	BBG00K2PDF81
FOLDGBX:XE	BBG00K2PDFB7
FOLDGBX:XJ	BBG00K2PDFC6
FOLDGBX:XL	BBG00K2PDFD5
FOLDGBX:XG	BBG00K2PDFF3
FOLDGBX:XO	BBG00K2PDFG2
FOLDGBX:XS	BBG00K2PDFL6
FOLDGBX:XA	BBG00K2PDFM5
FOLDGBX:E1	BBG00K2PDFN4
FOLDGBX:XT	BBG00K2PDFP2
FOLDGBX:XW	BBG00K2PDFQ1
FOLDGBX:XU	BBG00K2PDFR0
FOLDGBX:XV	BBG00K2PDFS9
FOLDGBX:XM	BBG00K2PDFT8
FOLDGBX:XQ	BBG00K2PDFW4
FOLDGBX:XX	BBG00K2PDFX3
FOLDGBX:XZ	BBG00K2PDFY2
FOLDGBX:EU	BBG00K2PDG07
FOLD:VG	BBG00X1NRHG1
FOLD:VP	BBG00X1S60H9
0HF9L:L1	BBG00Y7B36X0
AM6:GZ	BBG00Z0WX0K2
FOLD-RM:RM	BBG014BTY257
FOLD-RM:RX	BBG014BTY266
FOLD-RM:RN	BBG014BTY275
FOLD-RM:RP	BBG014BTY284
AM6:LA	BBG018H8BR49
AM6:LU	BBG018J1ZTQ8

Lakukan investasi terbaik dalam hidupmu fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Harga saham

Harga saham

TickerFOLD

ISINUS03152W1099

WKNA0MSMZ

Amicus Therapeutics Harga Saham

Kurs

Tinjauan

Fungsi Intraday

Total Return dan Perubahan Harga Relatif

Interpretasi dan Investasi

Amicus Therapeutics Sejarah Kurs

Amicus Therapeutics Saham Pendapatan, EBIT, Laba US03152W1099 · A0MSMZ

Pendapatan, Laba & EBIT

Pemahaman Pendapatan, EBIT dan Penghasilan

Analisis Tahunan dan Perbandingan

Memanfaatkan Harapan Investasi

Wawasan Investasi

Amicus Therapeutics Omzet, Laba, dan Histori EBIT

Amicus Therapeutics Saham Kennzahlen

GuV

Pendapatan dan Pertumbuhan

Margin Bruto

EBIT dan Margin EBIT

Pendapatan dan Pertumbuhan

Saham yang Beredar

Interpretasi Perbandingan Tahunan

Ekspektasi dan Prakiraan

Neraca

Memahami Neraca

Aset

Kewajiban

Ekuitas

Analisis Tahun Demi Tahun

Interpretasi Data

Amicus Therapeutics Saham Marjin US03152W1099 · A0MSMZ

Margen

Pemahaman Margin Kotor

Analisis Margin EBIT

Wawasan Margin Penjualan

Menginterpretasikan Harapan

Analisis Komparatif

Amicus Therapeutics Sejarah Margin

Amicus Therapeutics Saham Pendapatan, EBIT, Laba per Saham US03152W1099 · A0MSMZ

Pendapatan, EBIT dan Laba per Saham

Pendapatan per Saham

EBIT per Saham

Pendapatan per Saham

Nilai yang Diharapkan

Amicus Therapeutics Pendapatan, Laba, dan EBIT per Saham Sejarah

Amicus Therapeutics Saham dan Analisis Saham

Amicus Therapeutics Penilaian menurut Fair Value

Fair Value

Pemahaman Fair Value

Fair Value Berbasis Pendapatan

Fair Value Berbasis Pendapatan

Fair Value Berbasis Dividen

Harapan dan Proyeksi

Analisa Komparatif

Amicus Therapeutics Penilaian berdasarkan KGV, EBIT, dan KUV historis

Amicus Therapeutics Jumlah Saham US03152W1099 · A0MSMZ

Pendapatan, EBIT dan Laba per Saham

Pendapatan per Saham

EBIT per Saham

Pendapatan per Saham

Nilai yang Diharapkan

Amicus Therapeutics Estimasi Pendapatan

Amicus Therapeutics Kejutan Laba

Rating Eulerpool ESG untuk saham Amicus Therapeutics

Eulerpool World ESG Rating (EESG©)

66/ 100

🌱 Environment

👫 Social

🏛️ Governance

Lingkungan (Environment)

Sosial (Social)

Tata Kelola Perusahaan (Governance)

Amicus Therapeutics Struktur Pemegang Saham Aktie

Amicus Therapeutics Dewan Direksi dan Dewan Komisaris

Lakukan investasi terbaik dalam hidupmu
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Ticker
FOLD

ISIN
US03152W1099

WKN
A0MSMZ